The October 21 update was interesting $991m EBITD largely attributed to covid testing and increased genome testing to aid identification of variants. The omnicom variant and increased testing due to borders opening will make the November and December figures interesting. I would not be surprised if the EBITD for the full six months is over $1,500m. That 16% increase on last year may grow.
The October 21 update was interesting $991m EBITD largely...
Add SHL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$27.13 |
Change
-0.235(0.86%) |
Mkt cap ! $13.02B | |||
| Open | High | Low | Value | Volume |
| $27.22 | $27.33 | $27.06 | $6.128M | 225.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 272 | $27.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $27.13 | 495 | 14 |
View Market Depth
| Last trade - 15.30pm 11/10/2024 (20 minute delay) ? |
| SHL (ASX) Chart |